Delivery on both sales and gross margin above expectations EBIT revised up by 11-22% for '25e-'27e F...
Redeye provides its comment on Mendus’ Q1 2025 report.
Redeye comments on Invisio’s Q1-results which came in below our forecast with lower activity than ex...
EBITA SEK 271m (+3% vs. ABG, +6% vs. IR cons) We expect cons EBITA upgrades of 3-4% for '25e 15-13x ...
Redeye is revising near-term forecasts and valuation, following a weak Q1 and current market headwin...
Embracer becomes a shareholder in Starbreeze through a directed new share issue of 9% of the total n...
Redeye comments on Bredband2’s Q1 report where accelerated growth efforts resulted in a strong custo...
Sales +2% vs. ABGSCe, but EBITA 17% below Good customer intake, but margins weighted by investments ...
Sales -9%, adj. EBIT -2.6m vs. ABGSCe Miss driven by NW&FT and FW, GC&MP continues to grow Total liq...
Redeye gives its initial comments on the Q1 2025 report from Scandinavian ChemoTech, which was mostl...
Redeye provides an initial take following the release of Optomed’s Q1 2025 report.
Redeye comments on Hanza’s Q1 report, showing solid profitability in Main Markets while Other Market...
Acconeer reported Q1 net sales of SEK13.6m, a 20% y/y increase but 39% below Redeye's estimate.
Sales SEK 2.9m, EBIT adj. -12m vs. cons. 7.7m and -9.
Redeye provides an initial comment on OssDsign’s Q1 report, which was mainly in line with our sales ...
NoHo Partners reported seasonally small Q1 EBIT of EUR 7.
Redeye comments on Gentoo Media ahead of Q1-resuts (due 14 May) where we expect a seasonally softer ...
Sales beat and higher gross margin Adj. EBIT +45% vs ABGSCe Estimates likely to be revised up 7-10% ...
Physitrack’s Q1 2025 report marked a solid start to the year, with sales broadly in line and profita...
Cargo tonnes and the number of passengers declined slightly y/y in Q1.
